MA46099A - Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial - Google Patents
Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrialInfo
- Publication number
- MA46099A MA46099A MA046099A MA46099A MA46099A MA 46099 A MA46099 A MA 46099A MA 046099 A MA046099 A MA 046099A MA 46099 A MA46099 A MA 46099A MA 46099 A MA46099 A MA 46099A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- treatment
- diseases associated
- mitochondrial dysfunction
- mitochondrial
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004065 mitochondrial dysfunction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306094.0A EP3290039B1 (fr) | 2016-08-30 | 2016-08-30 | Composés pour traiter des maladies associées à un dysfonctionnement mitochondrial |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46099A true MA46099A (fr) | 2019-07-10 |
Family
ID=56896495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046099A MA46099A (fr) | 2016-08-30 | 2017-08-30 | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10857135B2 (fr) |
| EP (2) | EP3290039B1 (fr) |
| JP (1) | JP7065854B2 (fr) |
| KR (1) | KR20200011927A (fr) |
| CN (1) | CN110035758B (fr) |
| AU (1) | AU2017317651B2 (fr) |
| BR (1) | BR112019004236A2 (fr) |
| CA (1) | CA3034694A1 (fr) |
| ES (1) | ES2800917T3 (fr) |
| MA (1) | MA46099A (fr) |
| MX (1) | MX2019002369A (fr) |
| RU (1) | RU2019108824A (fr) |
| SG (1) | SG11201901689YA (fr) |
| WO (1) | WO2018041919A1 (fr) |
| ZA (1) | ZA201900997B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3290039B1 (fr) * | 2016-08-30 | 2020-03-25 | Amabiotics | Composés pour traiter des maladies associées à un dysfonctionnement mitochondrial |
| AU2019232139A1 (en) * | 2018-03-07 | 2020-10-08 | Amabiotics | Compounds for treating Alzheimer's disease |
| WO2020160183A1 (fr) * | 2019-01-29 | 2020-08-06 | Holobiome, Inc. | Procédés et compositions pour traiter et prévenir des troubles du système nerveux central et d'autres états provoqués par une dysbiose microbienne intestinale |
| US20230040247A1 (en) * | 2019-09-12 | 2023-02-09 | Amabiotics | Compounds for treating neurodegenerative diseases |
| WO2021048431A1 (fr) * | 2019-09-12 | 2021-03-18 | Amabiotics | Composés pour le traitement de l'ataxie |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936615A (ja) * | 1982-08-24 | 1984-02-28 | Takeda Chem Ind Ltd | 発がん予防剤 |
| JPH11506426A (ja) * | 1995-04-25 | 1999-06-08 | オリディグム コーポレイション | 代謝経路のｓ−アデノシルメチオニン調節ならびに診断および治療におけるその使用 |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| FR3002139B1 (fr) * | 2013-02-21 | 2015-06-19 | Amabiotics | Utilisation cosmetique de la queuine |
| GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| GB201417163D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
| EP3290039B1 (fr) * | 2016-08-30 | 2020-03-25 | Amabiotics | Composés pour traiter des maladies associées à un dysfonctionnement mitochondrial |
-
2016
- 2016-08-30 EP EP16306094.0A patent/EP3290039B1/fr active Active
- 2016-08-30 ES ES16306094T patent/ES2800917T3/es active Active
-
2017
- 2017-08-30 BR BR112019004236A patent/BR112019004236A2/pt not_active IP Right Cessation
- 2017-08-30 CN CN201780053445.8A patent/CN110035758B/zh active Active
- 2017-08-30 MA MA046099A patent/MA46099A/fr unknown
- 2017-08-30 CA CA3034694A patent/CA3034694A1/fr active Pending
- 2017-08-30 WO PCT/EP2017/071812 patent/WO2018041919A1/fr unknown
- 2017-08-30 AU AU2017317651A patent/AU2017317651B2/en not_active Expired - Fee Related
- 2017-08-30 EP EP17771680.0A patent/EP3506903A1/fr active Pending
- 2017-08-30 KR KR1020197008753A patent/KR20200011927A/ko active IP Right Grant
- 2017-08-30 JP JP2019532202A patent/JP7065854B2/ja active Active
- 2017-08-30 US US16/328,784 patent/US10857135B2/en active Active
- 2017-08-30 MX MX2019002369A patent/MX2019002369A/es unknown
- 2017-08-30 SG SG11201901689YA patent/SG11201901689YA/en unknown
- 2017-08-30 RU RU2019108824A patent/RU2019108824A/ru unknown
-
2019
- 2019-02-15 ZA ZA2019/00997A patent/ZA201900997B/en unknown
-
2020
- 2020-11-02 US US17/086,583 patent/US11684611B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201900997B (en) | 2020-05-27 |
| US10857135B2 (en) | 2020-12-08 |
| KR20200011927A (ko) | 2020-02-04 |
| JP7065854B2 (ja) | 2022-05-12 |
| JP2019526634A (ja) | 2019-09-19 |
| EP3290039B1 (fr) | 2020-03-25 |
| US20190224174A1 (en) | 2019-07-25 |
| CA3034694A1 (fr) | 2018-03-08 |
| AU2017317651A1 (en) | 2019-03-07 |
| EP3290039A1 (fr) | 2018-03-07 |
| SG11201901689YA (en) | 2019-03-28 |
| AU2017317651B2 (en) | 2022-12-15 |
| CN110035758A (zh) | 2019-07-19 |
| CN110035758B (zh) | 2023-06-16 |
| WO2018041919A1 (fr) | 2018-03-08 |
| MX2019002369A (es) | 2019-11-07 |
| ES2800917T3 (es) | 2021-01-05 |
| BR112019004236A2 (pt) | 2019-05-28 |
| US20210046056A1 (en) | 2021-02-18 |
| RU2019108824A3 (fr) | 2020-12-31 |
| EP3506903A1 (fr) | 2019-07-10 |
| US11684611B2 (en) | 2023-06-27 |
| RU2019108824A (ru) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45192A (fr) | Traitement d'association | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA45036A (fr) | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA45041A (fr) | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA51203A (fr) | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA47521A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| DK3612208T5 (da) | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA51525A (fr) | Traitement de minéraux | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |